RBC Capital analyst Conor McNamara initiated coverage of QuidelOrtho with an Outperform rating and $125 price target. The analyst believes the company will emerge from the pandemic with a much more diverse product and geographic presence, higher market share in more valuable end markets, and accelerated development and go-to-market plans with key product launches. He sees more sustainable growth and margin expansion opportunities for QuidelOrtho post pandemic.
Published first on TheFly